Johnson & Johnson traded at $254.02 this Tuesday June 30th, decreasing $4.49 or 1.74 percent since the previous trading session. Looking back, over the last four weeks, J&J lost 13.65 percent. Over the last 12 months, its price rose by 62.92 percent. Looking ahead, we forecast Johnson & Johnson to be priced at 249.36 by the end of this quarter and at 234.12 in one year, according to Trading Economics global macro models projections and analysts expectations.
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.